We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Australian Clinical Labs Limited | ASX:ACL | Australian Stock Exchange | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.02 | -0.77% | 2.59 | 2.58 | 2.60 | 2.64 | 2.58 | 2.62 | 132,235 | 02:15:35 |
From Jun 2019 to Jun 2024
Dr. Reddy's Laboratories Ltd. (500124.BY) said Wednesday it has received final approval from the U.S. Food and Drug Administration to sell a generic version of GlaxoSmithKline PLC's (GSK) Arixtra injection, which prevents blood clots after surgery.
The approval is for 2.5 milligram per 0.5-milliliter, 5.0 mg per 0.4-ml, 7.5 mg per 0.6-ml and 10 mg per 0.8-ml doses of fondaparinux sodium in pre-filled, single-dose syringes, the Indian generic drug maker said in a statement.
Dr. Reddy's will manufacture fondaparinux under license using a patented process developed by Alchemia Ltd. (ACL.AU).
-By Rumman Ahmed, Dow Jones Newswires; 91-9845104173; rumman.ahmed@dowjones.com
1 Year Australian Clinical Labs Chart |
1 Month Australian Clinical Labs Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
